Skip to main content
Erschienen in: Pathology & Oncology Research 3/2017

28.12.2016 | Original Article

Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients

verfasst von: Levente Kuthi, Alex Jenei, Adrienn Hajdu, István Németh, Zoltán Varga, Zoltán Bajory, László Pajor, Béla Iványi

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The morphotype and grade of renal cell carcinoma (RCC) in 928 nephrectomies were reclassified according to the 2016 WHO classification in order to analyze the distribution and outcomes of RCC subtypes in Hungary, to assess whether microscopic tumor necrosis is an independent prognostic factor in clear cell RCC, and to study whether a two-tiered grading (low/high) for clear cell and papillary RCC provides similar prognostic information to that of the four-tiered ISUP grading system. 83.4% of the cohort were clear cell, 6.9% papillary, 4.5% chromophobe, 2.3% unclassified, 1.1% Xp11 translocation, 1.1% clear cell papillary, 0.3% collecting duct and 0.1% mucinous tubular and spindle cell RCCs. RCC occurred in 16 patients with end-stage kidney disease and none of them displayed features of acquired cystic kidney disease-associated RCC. The 5-year survival rates were as follows: chromophobe 100%, clear cell papillary 100%, clear cell low-grade 96%, papillary type 1 92%, clear cell high-grade 63%, papillary type 2 65%, unclassified 46%, Xp11 translocation 20%, and collecting duct 0%. The 5-year survival rates in low-grade and high-grade papillary RCC were 95% and 59%, respectively. In clear cell RCC, only the grade, the stage and the positive surgical margin proved to be independent prognostic factors statistically. Overall, papillary RCC occurred relatively infrequently; microscopic tumor necrosis in clear cell RCC did not predict the outcome independently of the tumor grading; and the assignment of clear cell and papillary RCCs into low-grade or high-grade tumors was in terms of survival no worse than the ISUP grading.
Literatur
1.
Zurück zum Zitat Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO classification Tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO classification Tumours of the urinary system and male genital organs. International Agency for Research on Cancer, Lyon
2.
Zurück zum Zitat Srigley JR, Delahunt B, Eble JN et al (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489CrossRefPubMed Srigley JR, Delahunt B, Eble JN et al (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489CrossRefPubMed
3.
Zurück zum Zitat Delahunt B, Cheville JC, Martignoni G et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504CrossRefPubMed Delahunt B, Cheville JC, Martignoni G et al (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504CrossRefPubMed
4.
Zurück zum Zitat Reuter VE, Argani P, Zhou M, Delahunt B, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e35–e49PubMed Reuter VE, Argani P, Zhou M, Delahunt B, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e35–e49PubMed
5.
Zurück zum Zitat Steffens S, Janssen M, Ross FC et al (2014) The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Hum Pathol 45:2411–2416CrossRefPubMed Steffens S, Janssen M, Ross FC et al (2014) The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Hum Pathol 45:2411–2416CrossRefPubMed
6.
Zurück zum Zitat Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thompson RH, Boorjian SA, Cheville JC (2013) A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol 37:311–322CrossRefPubMed Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thompson RH, Boorjian SA, Cheville JC (2013) A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol 37:311–322CrossRefPubMed
8.
Zurück zum Zitat Genega EM, Ghebremichael M, Najarian R et al (2010) Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 134:873–879CrossRefPubMedPubMedCentral Genega EM, Ghebremichael M, Najarian R et al (2010) Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 134:873–879CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Gupta R, Billis A, Shah RB et al (2012) Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 36:1265–1278CrossRefPubMed Gupta R, Billis A, Shah RB et al (2012) Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 36:1265–1278CrossRefPubMed
10.
Zurück zum Zitat Williamson SR, Cheng L (2016) Clear cell renal cell tumors: not all that is “clear” is cancer. Urol Oncol 34:292.e17–292.e22CrossRef Williamson SR, Cheng L (2016) Clear cell renal cell tumors: not all that is “clear” is cancer. Urol Oncol 34:292.e17–292.e22CrossRef
11.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford
12.
Zurück zum Zitat Tarabeia J, Kaluski DN, Barchana M, Dichtiar R, Green MS (2010) Renal cell cancer in Israel: sex and ethnic differences in incidence and mortality, 1980-2004. Cancer Epidemiol 34:226–231CrossRefPubMed Tarabeia J, Kaluski DN, Barchana M, Dichtiar R, Green MS (2010) Renal cell cancer in Israel: sex and ethnic differences in incidence and mortality, 1980-2004. Cancer Epidemiol 34:226–231CrossRefPubMed
13.
Zurück zum Zitat Lipworth L, Morgans AK, Edwards TL et al (2016) Renal cell cancer histologic subtype distribution differs by race and sex. BJU Int 117:260–265CrossRefPubMed Lipworth L, Morgans AK, Edwards TL et al (2016) Renal cell cancer histologic subtype distribution differs by race and sex. BJU Int 117:260–265CrossRefPubMed
14.
Zurück zum Zitat Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Pummer K, Zigeuner R (2012) Renal cell carcinoma stage migration in a single European Centre over 25 years: effects on 5- and 10-year metastasis-free survival. Int Urol Nephrol 44:997–1004CrossRefPubMed Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Pummer K, Zigeuner R (2012) Renal cell carcinoma stage migration in a single European Centre over 25 years: effects on 5- and 10-year metastasis-free survival. Int Urol Nephrol 44:997–1004CrossRefPubMed
15.
Zurück zum Zitat Steffens S, Junker K, Roos FC et al (2014) Small renal cell carcinomas--how dangerous are they really? Results of a large multicenter study. Eur J Cancer 50:739–745CrossRefPubMed Steffens S, Junker K, Roos FC et al (2014) Small renal cell carcinomas--how dangerous are they really? Results of a large multicenter study. Eur J Cancer 50:739–745CrossRefPubMed
16.
Zurück zum Zitat Novara G, Ficarra V, Antonelli A et al (2010) Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58:588–595CrossRefPubMed Novara G, Ficarra V, Antonelli A et al (2010) Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 58:588–595CrossRefPubMed
17.
Zurück zum Zitat Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89:604–614CrossRefPubMed Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89:604–614CrossRefPubMed
18.
Zurück zum Zitat Rabjerg M, Mikkelsen MN, Walter S, Marcussen N (2014) Incidental renal neoplasms: is there a need for routine screening? A Danish single-center epidemiological study. APMIS 122:708–714CrossRefPubMed Rabjerg M, Mikkelsen MN, Walter S, Marcussen N (2014) Incidental renal neoplasms: is there a need for routine screening? A Danish single-center epidemiological study. APMIS 122:708–714CrossRefPubMed
19.
Zurück zum Zitat Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS (2014) Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol 45:59–64CrossRefPubMed Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS (2014) Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. Hum Pathol 45:59–64CrossRefPubMed
20.
Zurück zum Zitat Dhakal HP, McKenney JK, Khor LY, Reynolds JP, Magi-Galluzzi C, Przybycin CG (2016) Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol 40:141–154CrossRefPubMed Dhakal HP, McKenney JK, Khor LY, Reynolds JP, Magi-Galluzzi C, Przybycin CG (2016) Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol 40:141–154CrossRefPubMed
21.
Zurück zum Zitat Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141–153CrossRefPubMed Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141–153CrossRefPubMed
22.
Zurück zum Zitat Végső G, Toronyi E, Hajdu M et al (2011) Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant Proc 43:1261–1264CrossRefPubMed Végső G, Toronyi E, Hajdu M et al (2011) Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant Proc 43:1261–1264CrossRefPubMed
23.
Zurück zum Zitat Breda A, Luccarelli G, Rodriguez-Faba O et al (2015) Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol 33:1–7CrossRefPubMed Breda A, Luccarelli G, Rodriguez-Faba O et al (2015) Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol 33:1–7CrossRefPubMed
24.
Zurück zum Zitat Song C, Hong SH, Chung JS, Byun SS, Kwak C, Jeong CW, Seo SI, Jeon HG, Seo IY (2016) Renal cell carcinoma in end-stage disease: multi-institutional comparative analysis of survival. Int J Urol 23:465–471CrossRefPubMed Song C, Hong SH, Chung JS, Byun SS, Kwak C, Jeong CW, Seo SI, Jeon HG, Seo IY (2016) Renal cell carcinoma in end-stage disease: multi-institutional comparative analysis of survival. Int J Urol 23:465–471CrossRefPubMed
25.
Zurück zum Zitat Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23:2763–2771CrossRefPubMed Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23:2763–2771CrossRefPubMed
26.
Zurück zum Zitat Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183:1309–1315CrossRefPubMed Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC (2010) Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 183:1309–1315CrossRefPubMed
27.
Zurück zum Zitat Capitanio U, Cloutier V, Zini L et al (2009) A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJUI 103:1496–1500CrossRef Capitanio U, Cloutier V, Zini L et al (2009) A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJUI 103:1496–1500CrossRef
28.
Zurück zum Zitat Volpe A, Novara G, Antonelli A et al (2012) Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 110:76–83CrossRefPubMed Volpe A, Novara G, Antonelli A et al (2012) Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 110:76–83CrossRefPubMed
29.
Zurück zum Zitat Frees S, Kamal MM, Knoechlein L et al (2016) Differences in overall and cancer-specific survival of patients presenting with chromophobe versus clear cell renal cell carcinoma: a propensity score matched analysis. Urology. doi:10.1016/j.urology.2016.05.048 Frees S, Kamal MM, Knoechlein L et al (2016) Differences in overall and cancer-specific survival of patients presenting with chromophobe versus clear cell renal cell carcinoma: a propensity score matched analysis. Urology. doi:10.​1016/​j.​urology.​2016.​05.​048
30.
Zurück zum Zitat Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822–1834CrossRefPubMed Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822–1834CrossRefPubMed
31.
Zurück zum Zitat Diolombi ML, Cheng L, Argani P, Epstein JI (2015) Do clear cell papillary renal cell carcinomas have malignant potential? Am J Surg Pathol 39:1621–1634CrossRefPubMed Diolombi ML, Cheng L, Argani P, Epstein JI (2015) Do clear cell papillary renal cell carcinomas have malignant potential? Am J Surg Pathol 39:1621–1634CrossRefPubMed
32.
Zurück zum Zitat Cornejo KM, Dong F, Zhou AG et al (2015) Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome. Hum Pathol 46:1411–1417CrossRefPubMed Cornejo KM, Dong F, Zhou AG et al (2015) Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome. Hum Pathol 46:1411–1417CrossRefPubMed
33.
Zurück zum Zitat Warrick JI, Tsodikov A, Kunju LP et al (2012) Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Hum Pathol 45:1139–1146CrossRef Warrick JI, Tsodikov A, Kunju LP et al (2012) Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Hum Pathol 45:1139–1146CrossRef
34.
Zurück zum Zitat Pichler M, Hutterer GC, Chromecki TF, Pummer K, Mannweiler S, Zigeuner R (2013) Presence and extent of histological tumour necrosis is an adverse prognostic factor in papillary type 1 but not in papillary type 2 renal cell carcinoma. Histopathology 62:219–228CrossRefPubMed Pichler M, Hutterer GC, Chromecki TF, Pummer K, Mannweiler S, Zigeuner R (2013) Presence and extent of histological tumour necrosis is an adverse prognostic factor in papillary type 1 but not in papillary type 2 renal cell carcinoma. Histopathology 62:219–228CrossRefPubMed
35.
Zurück zum Zitat Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395–2400CrossRefPubMed Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395–2400CrossRefPubMed
36.
Zurück zum Zitat Lam JS, Shvarts O, Said JW et al (2005) Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103:2517–2525CrossRefPubMed Lam JS, Shvarts O, Said JW et al (2005) Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103:2517–2525CrossRefPubMed
37.
Zurück zum Zitat The Cancer Genom Atlas Network (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:135–145CrossRef The Cancer Genom Atlas Network (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:135–145CrossRef
38.
Zurück zum Zitat Becker A, Hickmann D, Hansen J et al (2016) Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--impact on prognosis. Eur J Surg Oncol 42:419–425CrossRefPubMed Becker A, Hickmann D, Hansen J et al (2016) Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--impact on prognosis. Eur J Surg Oncol 42:419–425CrossRefPubMed
40.
Metadaten
Titel
Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients
verfasst von
Levente Kuthi
Alex Jenei
Adrienn Hajdu
István Németh
Zoltán Varga
Zoltán Bajory
László Pajor
Béla Iványi
Publikationsdatum
28.12.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2017
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0179-x

Weitere Artikel der Ausgabe 3/2017

Pathology & Oncology Research 3/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.